New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 18, 2014
04:55 EDTNVDQ, NVDQ, NVDQ, MMSI, MMSI, MMSI, TEAR, TEAR, TEAR, ABAX, ABAX, ABAX, ELGX, ELGX, ELGX, VASC, VASC, VASCLazard to hold a conference
6th Annual MedTech, Diagnostics & Healthcare IT Snowbird Conference is being held in Snowbird, Utah on March 18-20.
News For NVDQ;MMSI;TEAR;ABAX;ELGX;VASC From The Last 14 Days
Check below for free stories on NVDQ;MMSI;TEAR;ABAX;ELGX;VASC the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 24, 2014
16:19 EDTABAXAbaxis reports Q1 EPS 21c, consensus 19c
Subscribe for More Information
July 23, 2014
13:36 EDTNVDQIntuitive Surgical rises after Q2 EPS, revenue beat expectations
Subscribe for More Information
July 22, 2014
16:20 EDTVASCVascular Solutions sees Q3 GAAP EPS 19c-20c, consensus 18c
Sees Q3 revenue $30.5M-$31.5M, consensus $31.05M. Q3 revenue view represents growth of approximately 11% from $28.0M in the Q3 of FY13. The company's net earnings guidance for the Q3 includes $800,000 in non-cash stock-based compensation, $400,000 in amortization of intangibles, $370,000 for the U.S. medical device excise tax, and an assumed 36% effective income tax rate.
16:18 EDTVASCVascular Solutions raises FY14 GAAP EPS view to73c-77c from 71c-75c
Vascular Solutions is raising the bottom-end of its net revenue guidance for FY14 to $123M, resulting in a new range of $123M- $125M. The mid-point of the new range represents an increase of 12% from $110.5M in 2013. Previously, the company's revenue guidance range for 2014 was $121M-$125M. Consensus is for FY14 revenue $123.22M. Vascular Solutions is also raising its GAAP earnings guidance for 2014 to a range of $0.73-$0.77 per share, representing an increase of 12%-18% over the $0.65 reported in 2013. The company's previous EPS guidance range for 2014 was $0.71-$0.75. Included in the company's 2014 earnings guidance are $3.8M in non-cash stock-based compensation, $1.6M in amortization of intangibles, between $1.4M-$1.5M for the U.S. medical device excise tax, and an assumed 36% tax rate. Consensus is for FY14 EPS 72c.
16:14 EDTVASCVascular Solutions reports Q2 adj. EPS 20c, consensus 18c
Subscribe for More Information
07:08 EDTABAXLife Sciences highlights this week at Canaccord
Canaccord highlighted six diagnostic names that report this week and recommends buying Top Pick IDEXX (IDXX) into the print given strong recurring razor/razorblade sales and consistent organic growth. The analyst expects Hold rated Quest Diagnostics (DGX) to report upside to Street estimates of $1.06/$1.882B, Quidel (QDEL) to have an uneventful report, Exact Sciences (EXAS) to provide an update on numerous catalysts near-term and Abaxis (ABAX) to report earnings below consensus. Lastly, the firm is cautious on Meridian Bioscience (VIVO) following a competitor report last week.
July 15, 2014
07:18 EDTNVDQNovadaq has strong products, improved sales team, says Stifel
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use